Biotech News

Stock index futures edged up on Tuesday after earnings from Coca Cola and Johnson & Johnson and ahead of economic data including inflation and manufacturing.

World markets turned lower on Tuesday amid concerns about instability in Ukraine, the value of technology stocks and an economic slowdown in China.

1 spot in the Tampa Bay Times' Top Workplaces list for 2014. It is the third time in five years for ASI to earn the a... )--The recently discovered fracture at the Wanapum Dam's spillway structure does not currently impact bond ratings for the project's owner, the Public Utility District No.

Major U.S. stock indexes are turning higher in the late afternoon as the market shuffles between gains and losses.

Scientists using a remote-controlled robot submersible have discovered a new species of poisonous sponge in deep waters off San Diego.

Beazer Homes, Ryland Group and other homebuilder stocks fell after a survey showed that the industry's confidence in the housing market remains low.

Once you're logged in, at the top of each article, video or slideshow you will see a list of your Facebook friends who recently visited Choose to share stories you'e read with your friends or turn sharing OFF to keep your reading experience anonymous .

Johnson & Johnson says its first-quarter profit rose 8 percent, because of restrained costs and a big jump in prescription drug sales.

A coformulation of sofosbuvir and ledipasvir taken for as little as 8 weeks produced high sustained response rates across the board for participants in the phase 3 ION trials, including people with HCV genotype 1 starting treatment for the first time, prior non-responders and people with liver cirrhosis, according to findings presented last week at ... (more)

Generic drugmaker Akorn Enterprises Inc has won U.S. antitrust approval to buy rival Hi-Tech Pharmacal Inc on condition that it sell three generic prescription eye medications and two generic topical anesthetics, the Federal Trade Commission said on Monday.

Merck & Co said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy drug Grastek, becoming the second such immunotherapy treatment to be given the go-ahead in recent weeks.

The firm currently has a $54.00 target price on the stock, up from their previous target price of $45.00.

Once you're logged in, at the top of each article, video or slideshow you will see a list of your Facebook friends who recently visited Choose to share stories you'e read with your friends or turn sharing OFF to keep your reading experience anonymous .

The stock market today felt a bit like a game of musical chairs with no one quite sure where it would end up.

Whistle-blower. Greg Thorpe, a former sales representative for GlaxoSmithKline, sits at a desk in Florida with papers from the case in which he alleged the company encouraged doctors to prescribe antidepressants to children when the FDA had not approved the drugs for pediatric use.

The benchmark S&P/ASX 200 Index tumbled 69.7 points, or 1.3 per cent, to 5358.9, while the broader All Ordinaries also lost 1.3 per cent to 5353.6 with all major sectors affected.

Now scientists are starting to use sophisticated DNA sequencing technology to determine if these "exceptional responders" carry gene variations that can lead to new treatment approaches, better targeted therapies or even the re- emergence of experimental drugs once deemed failures.

GlaxoSmithKline is facing a criminal investigation in Poland for allegedly bribing doctors to promote its lung drug Seretide, adding to problems for a company already accused of corruption in China and Iraq.

The wrenching selloff in U.S. high-growth technology and biotech shares could leave investors braced for more than a minor pullback when earnings pick up speed this week.

GlaxoSmithKline Plc is facing a criminal investigation in Poland for allegedly bribing doctors to promote its asthma drug Seretide, BBC Panorama reported on Sunday.